Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.At a meeting with financial analysts in connection with the American Society of Clinical Oncology annual meeting in Chicago, Pfizer has unveiled details of its plans to advance key cancer compounds into phase III trials during 2007.
Subscribe to our email newsletter
The company highlighted several oncology compounds that are currently in phase III trials, as well as additional compounds expected to advance into phase III trials in the next year.
Lined up for Sutent, which is currently under phase III investigation in breast cancer, are trials in non-small cell lung cancer (NSCLC), colorectal cancer and liver cancer, while Axitinib is scheduled to enter a phase III trial in pancreatic cancer, and CP-751,871 is set to be studied in a phase III NSCLC program.
In addition, both CP 675,206, which is currently in a phase III melanoma program, and PF 3,512,676, which is under study in NSCLC, will be entering into new phase III study programs, further details of which have yet to be given,
“We have compounds in phase III, or nearing phase III, which address more than 70% of deaths due to various cancer types,” commented Dr Charles Baum, vice president of Pfizer global R&D. “We continue to move our pipeline closer to regulatory submissions and closer to broad availability for the cancer patients that could benefit from them.”